Freedom Capital downgraded Amgen (AMGN) to Hold from Buy with a price target of $375, up from $360. The firm views the company’s Q4 report as “strong.” However, the shares are nearing fair value and while loss of exclusivity headwinds remain for Amgen, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Invesco QQQ Trust ETF (QQQ) Daily Update, 2/9/2026
- Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma
- Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch
- Amgen Earnings Call: Broad Growth Amid Manageable Risks
- Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act